PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19649689-4 2009 Accordingly, we evaluated the safety and efficacy of Le-IFN-alpha in patients intolerant to peg-IFNs. peg-ifns 92-100 interferon alpha 1 Homo sapiens 56-59 25831972-7 2015 RESULTS: A subset of patients suffering from pegylated IFN-alpha-associated exanthemas displayed positive intradermal tests to PEG-IFNs but not to conventional IFN (11/22). peg-ifns 127-135 interferon alpha 1 Homo sapiens 55-64 19649689-16 2009 The data indicate that Le-IFN-alpha plus ribavirin is a useful and effective treatment for CHC patients who are intolerant to peg-IFNs. peg-ifns 126-134 interferon alpha 1 Homo sapiens 26-29 19139808-11 2009 CONCLUSIONS: These results suggest that an early retreatment with leukocyte IFN-alpha may be a safe and valid therapeutic option among difficult-to-treat HCV cirrhotic patients who cannot tolerate PEG-IFNs. peg-ifns 197-205 interferon alpha 1 Homo sapiens 76-85 12739994-8 2003 Both PEG-IFNs are given by a once-weekly injection and as monotherapy, they are more effective than standard IFN-alpha. peg-ifns 5-13 interferon alpha 1 Homo sapiens 109-118